U.S. General Merchandise and Department Stores Stock News

In recent trading, DXP Enterprises has been caught up in past market volatility tied to shifting U.S. trade tensions and tariff threats, while investors also look ahead to an earnings report that is expected to show lower EPS alongside higher revenue. The stock’s moves highlight how external policy uncertainty can weigh on sentiment even when consensus expectations point to continued sales growth and constructive analyst rankings. We’ll now examine how trade-policy uncertainty and the...

If you are wondering whether Pathward Financial is still fairly priced or starting to look expensive at current levels, you are not alone. The stock recently closed at US$85.43, with returns of 13.5% over 7 days, 16.3% over 30 days, 18.9% year to date, 6.9% over 1 year, 76.7% over 3 years and 120.1% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on how Pathward Financial is positioned within the US...

Why Celsius Holdings Is Back on Investors’ Radar Celsius Holdings (CELH) is drawing fresh attention as investors react to rapid revenue growth, broader distribution across key channels, and operating margins around 20%, all alongside new leadership additions tied to major beverage industry experience. See our latest analysis for Celsius Holdings. After a mixed few months, with a 19.63% 1 month share price return offset by an 11.89% 3 month share price decline, Celsius Holdings now trades at...

Costco faces a class action lawsuit alleging false advertising over preservatives in its $4.99 rotisserie chicken. The complaint claims Costco misled shoppers about ingredients and challenges the accuracy of its product labeling. The case raises broader questions about transparency in food labeling and how retailers describe signature products. For investors watching NasdaqGS:COST, the lawsuit comes at a time when Costco shares trade around $977.67, with a 30 day return of 11.9% and a 3...

Why SkyWater Technology is on investors’ radar SkyWater Technology (SKYT) has drawn fresh attention after a sharp share price move, with the stock up about 78% over the past month and roughly 97% in the past 3 months. See our latest analysis for SkyWater Technology. That sharp 77.9% 1 month share price return and 96.7% 3 month share price return, from a latest share price of $32.35, sits alongside a 1 year total shareholder return of about 230%. This suggests momentum has been building...

TowneBank (TOWN) is on investors’ radar after recent share price gains over the past month and the past 3 months, prompting closer attention to how its current valuation lines up with fundamentals. See our latest analysis for TowneBank. The recent share price strength, including a 7.30% 30 day share price return and 8.82% year to date share price return to US$36.15, sits alongside a 5 year total shareholder return of 78.19%, pointing to momentum that has built over a multi year period. If...

FDA Breakthrough designation puts pemvidutide in focus Altimmune (ALT) has drawn fresh attention after the FDA granted Breakthrough Therapy Designation to its lead candidate pemvidutide for MASH, based on mid stage trial data showing significant disease resolution. See our latest analysis for Altimmune. The FDA Breakthrough Therapy news has arrived during a period of building momentum for Altimmune, with the 7 day share price return of 33.49% and year to date share price return of 61.25%...

If you are wondering whether Mastercard's current share price fairly reflects its long term potential, starting with a clear view of value can help you decide where it might fit in your portfolio. The stock closed at US$527.36, with a 2.2% decline over the last 7 days and a 9.0% decline over the last 30 days, while still showing longer term returns of 44.6% over 3 years and 68.8% over 5 years. Recent news coverage has focused on Mastercard's ongoing role in global digital payments and its...

Halliburton (NYSE:HAL) has launched the Next-Generation Energy Accelerators Joint Lab, known as NEX Lab, in partnership with Singapore’s A*STAR and the Economic Development Board. The joint lab will focus on developing and commercializing advanced energy technologies, including well completion solutions and low carbon applications. The initiative strengthens Halliburton’s research and development footprint in Asia and supports the growth of local technical talent. For investors watching the...

In recent days, analysts at firms including KeyBanc and Guggenheim have reinforced their positive views on Dycom Industries, citing improved margins, expanding fiber-to-the-home work, and new data center fiber opportunities alongside the completed acquisition of Power Solutions. This combination of bullish analyst coverage, federal broadband initiatives such as the BEAD program, and broader exposure to data center electrical projects is reshaping how investors view Dycom’s long-term role in...

Earlier in January, Deutsche Bank highlighted Badger Meter as well-positioned within the water technology sector, pointing to the appeal of smart water solutions, stronger utility water sales, and contribution from recent acquisitions. This contrasts with Barclays’ earlier Underweight initiation and underscores how differing analyst views are centering on valuation, sector recovery prospects, and the role of acquisitions like the SmartCover purchase in shaping Badger Meter’s...

Why Pharvaris Stock Is Back on Traders’ Radars Pharvaris (PHVS) has drawn fresh attention after a quarterly earnings report that surpassed analysts’ consensus expectations, followed by multiple brokerages reiterating positive ratings and increasing their estimates for the stock. See our latest analysis for Pharvaris. After the recent earnings surprise and upbeat broker commentary, Pharvaris has kept positive momentum, with a 21.81% 90 day share price return and a 53.11% 1 year total...

United Therapeutics, through its Miromatrix subsidiary, reported past positive phase 1 safety results for miroliverELAP, an investigational external liver assist device using a bioengineered liver, in five acute liver failure patients who were not eligible for transplant. The study’s survival outcome during treatment and absence of unexpected serious adverse events over 32 days highlight the company’s push into organ alternatives to address the shortage of transplantable livers. We’ll now...

Enterprise Financial Services Corp has already released its latest quarterly results and highlighted a solid third quarter, with loan growth returning to an annualized 6% and deposit growth running even higher, supported by its acquisition of 12 branches adding about US$650,000,000 in deposits and US$300,000,000 in loans. Analysts had expected around US$187,100,000 in quarterly revenue and earnings of roughly US$1.36–US$1.37 per share, and their largely unchanged estimates ahead of the...

NNN REIT (NYSE:NNN) has affirmed its quarterly dividend, maintaining its current payout to shareholders. The company continues its 36-year streak of consecutive annual dividend growth. Management points to rent growth and new acquisitions as key supports for the dividend policy. NNN REIT focuses on single tenant, net lease retail properties, which are generally built around long term leases and predictable rental streams. For income focused investors, the reaffirmed dividend and long...

If you are wondering whether Arm Holdings at around US$114.73 is a bargain or already priced for perfection, you are not alone. The stock has moved 7.1% over the last 7 days and 4.0% over the last 30 days, while the 1 year return sits at a 23.2% decline, which can change how investors think about both upside and risk. Recent attention on Arm Holdings has focused on its role at the center of global semiconductor design, with investors watching how its chip architectures power everything from...

For readers considering whether Ramaco Resources at US$22.09 offers value after its recent run, this article breaks down what the current price might be implying about the stock. The share price has gained 23.5% over the last 30 days, with an 18.1% return year to date and a 138.6% return over the past year, while the last 7 days saw a 1% decline. Recent coverage has focused on Ramaco Resources as part of ongoing evergreen monitoring of coal and materials companies, with investors paying...

Fair Isaac (NYSE:FICO) has launched new AI driven solutions for financial services. The tools extend the company’s offering beyond traditional FICO credit scores into broader automated decisioning and analytics. The rollout is aimed at supporting lenders with loan decisions, fraud detection, and targeted customer offers. For you as an investor, this move shows how Fair Isaac is leaning further into software and analytics that sit behind everyday credit decisions. NYSE:FICO has long been...

Exelon stock triggered review With no single event driving Exelon (EXC) into focus, investors may be looking at its recent share performance and financial profile to reassess how this regulated utility fits into a diversified portfolio. See our latest analysis for Exelon. At a share price of US$44.55, Exelon has seen a 2.3% 1 month share price return but a 6.6% 3 month share price decline, while its 1 year total shareholder return of 13.4% points to steadier, income supported progress for...

Why Globant stock is attracting fresh attention With no single headline event driving Globant (GLOB) today, investors are instead focusing on how its current share price of US$69.19 lines up with recent returns and the company’s reported fundamentals. See our latest analysis for Globant. Globant’s recent 1-day, 7-day and 90-day share price returns of 0.22%, 1.45% and 13.84% suggest some short term momentum, although the 1-year total shareholder return of a 66.67% loss shows longer term...

Johnson & Johnson (NYSE:JNJ) reported positive Phase 3 MajesTEC-9 results for TECVAYLI in relapsed or refractory multiple myeloma. The company also released new CAPLYTA data showing improved remission rates in major depressive disorder. Johnson & Johnson presented a wide set of neuropsychiatry research updates, highlighting progress across its pharmaceutical pipeline. For investors watching NYSE:JNJ, these clinical updates arrive with the stock trading at $221.49. Over the past year, the...

President Donald Trump has filed a US$5b lawsuit against JPMorgan Chase (NYSE:JPM) and CEO Jamie Dimon. The suit alleges the bank closed accounts linked to Trump and affiliated entities for political reasons after the January 6 Capitol riot. JPMorgan Chase denies the claims, saying account closures relate to legal or regulatory risk considerations. For you as an investor, this dispute centers on JPMorgan Chase's core business role as the largest US bank, with reach across consumer banking,...

Viatris Inc. recently launched Inpefa (sotagliflozin) in the United Arab Emirates, its first commercialization of the heart failure treatment in its territories outside the U.S. and Europe, following an exclusive licensing deal with Lexicon Pharmaceuticals for markets beyond those regions. This marks Viatris’ first international rollout of a dual SGLT1/2 inhibitor for cardiovascular disease, highlighting an effort to broaden its innovative portfolio and expand patient access in key markets...

Why Plains GP Holdings (PAGP) is on investors’ radar Plains GP Holdings (PAGP) has caught attention after a strong past 3 months, with the stock showing a month-long gain as well and meaningful multi year total returns that invite closer scrutiny. See our latest analysis for Plains GP Holdings. At a share price of US$20.42, Plains GP Holdings has recently seen a 30 day share price return of 8.5% and a 90 day share price return of 15.6%. Its 5 year total shareholder return of 233.9% points to...